CTRI/2020/01/022962尚未招募4 期
A Comparative evaluation of efficacy of CPP-ACP varnish with and without papain gel on the remineralisation of white spot lesions using laser fluorescence
King Georges Medical University0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Teeth with white spot lesions due to poor oral hygiene
- •prolonged plaque accumulation and teeth undergoing fixed orthodontic treatment.
- •Patients not using any extensive fluoride regimes.
排除标准
- •Teeth with caries activity or periodontal disease
- •Teeth with associated developmental abnormalities like amelogenesis imperfecta, dentinogenesis imperfecta.
- •Teeth with fluorosis.
- •Teeth with hypoplastic white spots.
- •Patients with history of xerostomia.
- •Patients who are on any medications that alter the salivary flow.
- •Patients with hypoplastic enamel defects, cleft lip and palate deformities, orofacial syndrome, other syndromes and multiple restorations on the facial surfaces and
- •patients with a known history of allergy to milk protein.
研究者
相似试验
招募中
2 期
Comparison of the effect of CPP-ACPF and propolis in the treatment of dentin sensitivityIRCT20120901010703N4Esfahan University of Medical Sciences20
已完成
不适用
Comparing the effect of two different pastes on dental plaque pH changes and caries prevention after sugar consumption.Dental careis.Dental cariesIRCT2012113010086N2Chancellor of research center of islamic azad dental university,Tehran40
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-BEAcerta Pharma, BV60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-GBAcerta Pharma B.V.60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-ESAcerta Pharma, BV80